Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles

Robert S. Foti and Jan L. Wahlstrom
Drug Metabolism and Disposition March 2008, 36 (3) 523-528; DOI: https://doi.org/10.1124/dmd.107.019265
Robert S. Foti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan L. Wahlstrom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 36 no. 3 523-528
DOI 
https://doi.org/10.1124/dmd.107.019265
PubMed 
18048485

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received October 15, 2007
  • Accepted November 26, 2007
  • Published online February 22, 2008.

Article Versions

  • Earlier version (November 29, 2007 - 07:35).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Robert S. Foti and
  2. Jan L. Wahlstrom
  1. Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, Washington
  1. Address correspondence to:
    Dr. Jan Wahlstrom, Amgen, Inc, Pharmacokinetics and Drug Metabolism, 1201 Amgen Court West, Mail Stop AW2/D2262, Seattle, WA 98119. E-mail: janw{at}amgen.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to February 2023

AbstractFullPdf
Aug 201713316
Sep 201712814
Oct 201723819
Nov 201715419
Dec 201732911
Jan 20180457
Feb 201803010
Mar 201803510
Apr 201838820
May 201826214
Jun 2018010521
Jul 201817516
Aug 201806019
Sep 201809222
Oct 2018011811
Nov 2018316019
Dec 20181536024
Jan 2019131209
Feb 2019126101
Mar 201912375
Apr 2019128219
May 20198595
Jun 20199067
Jul 201993109
Aug 20194454
Oct 201969108
Nov 201910698
Dec 2019112154
Jan 20207960
Feb 202067124
Mar 20208258
May 20203513
Jun 20205043
Jul 20203920
Aug 20204543
Sep 20204152
Oct 20204046
Nov 20205925
Dec 20203035
Jan 202152165
Feb 202128246
Mar 2021116116
Apr 20212545
May 20217351
Jun 202134164
Jul 20211543
Aug 202154138
Sep 20212081
Oct 20212071
Nov 20212334
Dec 20213213
Jan 20223652
Feb 20222910
Mar 20223975
Apr 20223543
May 20225896
Jun 20224000
Jul 202241310
Aug 20225022
Sep 20222432
Oct 20221990
Nov 20223637
Dec 20225234
Jan 20236076
Feb 20231000

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 36 (3)
Drug Metabolism and Disposition
Vol. 36, Issue 3
1 Mar 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles

Robert S. Foti and Jan L. Wahlstrom
Drug Metabolism and Disposition March 1, 2008, 36 (3) 523-528; DOI: https://doi.org/10.1124/dmd.107.019265

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles

Robert S. Foti and Jan L. Wahlstrom
Drug Metabolism and Disposition March 1, 2008, 36 (3) 523-528; DOI: https://doi.org/10.1124/dmd.107.019265
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Series-Compartment Models of Hepatic Elimination
  • Warfarin PBPK Model with TMDD Mechanism
  • Identification of payload-containing catabolites of ADCs
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics